Fitness for Brain Optimization for Late-Life Depression (FIT BOLD)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04670510 |
Recruitment Status :
Recruiting
First Posted : December 17, 2020
Last Update Posted : August 18, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Depression in Old Age | Other: On-site AE Other: At-home AE Other: Social Engagement (SE) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Investigator, Outcomes Assessor) |
Primary Purpose: | Basic Science |
Official Title: | Aerobic Exercise for Optimizing Cognitive and Brain Health in Remitted Late-Life Depression |
Actual Study Start Date : | August 4, 2021 |
Estimated Primary Completion Date : | March 2026 |
Estimated Study Completion Date : | June 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Aerobic Exercise
The Aerobic Exercise (AE) condition will involve 150-minutes of moderate-intensity AE per week for 6-months and will involve a graded decline in supervision. Supervised AE will occur in groups, though each participant's AE prescription will be personalized based on baseline exercise capacity, as assessed by a maximal cardiopulmonary fitness test. Supervised AE sessions will involve the treadmill, elliptical, and/or bike, and routines will be varied to promote adherence. Supervised AE sessions will gradually increase to 50-minutes per session; however, participants will be encouraged to engage in home-based AE sessions according to their own preference of length and frequency in order to achieve 150 minutes of AE per week.
|
Other: On-site AE
Participants will attend on-site supervised AE sessions 3 times per week for the first 6 weeks, twice weekly for weeks 7-12; once weekly for weeks 13-18. All supervised sessions will start and end with 5-minute warm-up and cool-down and will involve exercise on the treadmill, elliptical, and/or bike. During AE sessions, participants will exercise so that their heart rate is approximately 65% of their peak heart rate and gradually increase the intensity of exercise so that their heart rate is between 70 and 85% of their peak heart rate. All participants will wear heart rate monitors and encouraged to exercise in their target heart rate zone. Supervised AE sessions will gradually increase to 50-minutes per session Other: At-home AE Participants will increase at-home AE during the 6-month intervention period with weeks 19-26 occurring entirely at-home. As participants transition to home-based exercise, they will be equipped with a polar heart rate monitor and will be instructed to use this to record average heart rate during each exercise session. On a log sheet, they will record both average heart rate during exercise and average subjective rating of perceived exertion (RPE) during each exercise session. |
Active Comparator: Social Engagement
The Social Engagement (SE) condition will be designed to control for the social component of the AE intervention (i.e., supervised on-site sessions with professional staff, frequent phone contact from study staff). A variety of enjoyable group-based activities centered around the dimensions of wellness (spiritual wellness, physical wellness, emotional wellness, etc.) will be scheduled throughout the intervention. This condition will involve once weekly meetings (grand total of ~26 sessions). Some participants will meet in-person and others will meet remotely via zoom (this will vary week to week) to increase flexibility to accommodate participant availability to attend as many sessions as possible.
|
Other: Social Engagement (SE)
To control for the social component of the AE intervention participants in the SE group will be invited to attend at total of 25 group meetings over the course of the 6-month study period. |
- Change from baseline in Cardiovascular Fitness at 6 months [ Time Frame: Baseline and 6-months ]Cardiorespiratory fitness will be measured via a cardiopulmonary exercise test (CPET) indicated by maximal VO2 on a motorized treadmill. while measuring oxygen utilization via Parvo Medics True one metabolic cart. The test follows a modified Balke protocol in which speed remains constant with the intensity being increased every two minutes via a raise of 2.0% of the incline. The speed was an agreed upon speed between participant and staff (between 2.0 and 4.0 mph). The test will conclude when the participant reaches 85% of age predicted maximal heart rate, rating of perceived exertion (RPE) equal to or greater than 15 for those who have blunted heart rate response due to beta block medication, or volitional termination by participant.
- Changes from baseline in Brain Structure and Function at 6 months [ Time Frame: Baseline and 6-months ]Brain imaging conducted with a 7 Tesla scanner. Of particular interest are changes in hippocampal volume. This measurement is reported in mm^3, with higher numbers indicating higher levels of gray matter in the hippocampal region. Changes in prefrontal cortical thickness are also of interest, measured in mm. Brain functional network changes of interest are changes in intra- and inter-connectivity of the default-mode and executive control large-scale brain networks.
- Changes from baseline in depressive symptoms at 6 months [ Time Frame: Baseline and 6-months ]Given that all participants will have a recent history of depression, and may have lingering low level symptoms or may even relapse, depressive symptoms will be assessed using the Montgomery Asberg Depression Rating Scale (MADR; score ranges from 0 [better] to 60 [worse]), a clinician administered measure of depression severity.
- Depressive Symptoms [ Time Frame: Continuously up to every 6-weeks for 6 months ]For the frequent assessment of depressive symptoms during the intervention while minimizing participant and clinician burden, the Patient Health Questionnaire-9 item version (PHQ-9; score ranges from 0 [better] to 27 [worse]), a self-report questionnaire, will be administered.
- Change from baseline in Cognitive Function at 6 months [ Time Frame: Baseline and 6-months ]Assessed with a comprehensive Neuropsychological Battery. The primary cognitive outcome will be assessed using a composite score (mean) of standardized scores (Z-scores) from the following executive functioning tests from the NIH toolbox: 1) Dimensional Change Card Sort Test (set-shifting), Flanker Inhibitory Control and Attention Test (inhibition), List Sorting Working Memory Test (working memory).
- During-intervention physical activity levels [ Time Frame: Continuously up to every 2 months for 6 months ]Participants will wear wrist Actigraphy to monitor physical activity levels
- Change from baseline in amount of physical activity at 6 months [ Time Frame: Baseline and 6-months ]Participants will wear wrist Actigraphy to monitor amount of physical activity
- Changes from baseline in intensity of physical activity at 6 months [ Time Frame: Baseline and 6-months ]Participants will wear wrist Actigraphy to monitor intensity of physical activity
- Change from baseline in Subjective Cognitive Function at 6 months [ Time Frame: Baseline and 6-months ]Subjective reports of cognitive functioning will also be assessed using the Measurement of Everyday Cognition (E-Cog; scores range from 1 [better] to 4 [worse]), given that those with a recent history of LLD may be likely to underestimate their cognitive abilities.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 60 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Men and women 60+ years
- Major Depressive Episode in older adulthood (since age 55)
- Current level of depressive symptoms does not meet criteria for a Major Depressive Episode
- Ambulatory without pain or the assistance of walking devices
- Able to speak and read English
- Exercise level of <100 minutes per week on average
- Medical clearance by primary care physician (PCP)
- Living in community for duration of the study
- Reliable means of transportation
- No diagnosis of a neurological disease
- Eligible to undergo MRI
Exclusion Criteria:
- Current diagnosis of a Major Depressive Episode
- Psychosis
- Significant suicide risk (i.e., current, active suicidal ideation with a plan)
- Electroconvulsive therapy within the past 12 months
- Engaging in moderate-intensity exercise >100 minutes per week on average
- Current treatment for cancer - except non-melanoma skin
- Neurological condition (MS, Parkinson's, Dementia, MCI) or brain injury (Stroke)
- Substance Use disorder in the past 3-months
- Current treatment for congestive heart failure, angina, uncontrolled arrhythmia, deep vein thromboses (DVT) or other cardiovascular event
- Myocardial infarction, coronary artery bypass grafting, angioplasty or other cardiac condition in the past year including uncontrolled hypertension
- Regular use of an assisted walking device
- Presence of metal implants (pacemaker, stents) that would be MR ineligible
- Claustrophobia
- Color Blindness
- Significant visual or hearing impairments that would preclude neuropsychological assessment or communication with study staff via a virtual format (videoteleconference)
- Not fluent in English
- Not medically cleared by PCP
- Traveling consecutively for 3+ weeks during the study
- MOCA (<20 to exclude) and MADRS (>9 to exclude)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04670510
Contact: Michelle Zmuda | 412-246-6487 | zmudamd@upmc.edu | |
Contact: Sarah Kimutis, MBA | 412-246-6487 | kimutiss@upmc.edu |
United States, Pennsylvania | |
UPMC Western Psychiatric Hospital | Recruiting |
Pittsburgh, Pennsylvania, United States, 15213 | |
Contact: Michelle Zmuda 412-246-6487 zmudamd@upmc.edu |
Principal Investigator: | Swathi Gujral, PhD | University of Pittsburgh |
Responsible Party: | Swathi Gujral, Assistant Professor of the Department of Psychiatry at the University of Pittsburgh, School of Medicine, University of Pittsburgh |
ClinicalTrials.gov Identifier: | NCT04670510 |
Other Study ID Numbers: |
STUDY20080088 K23MH125074 ( U.S. NIH Grant/Contract ) |
First Posted: | December 17, 2020 Key Record Dates |
Last Update Posted: | August 18, 2023 |
Last Verified: | August 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Current and future investigators, both internal and external, may have access to de-identified data; however only group data would be shared. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Depression Exercise Late-Life Cognitive Impairment Brain Health |
Depression Depressive Disorder Behavioral Symptoms Mood Disorders Mental Disorders |